123 related articles for article (PubMed ID: 21314247)
1. Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups.
Pettengell R; Schwenkglenks M
Leuk Lymphoma; 2011 Jun; 52(6):1133-6. PubMed ID: 21314247
[No Abstract] [Full Text] [Related]
2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
3. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks M;
Br J Haematol; 2009 Mar; 144(5):677-85. PubMed ID: 19055662
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
[TBL] [Abstract][Full Text] [Related]
6. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
[TBL] [Abstract][Full Text] [Related]
7. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
[TBL] [Abstract][Full Text] [Related]
8. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
9. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
[TBL] [Abstract][Full Text] [Related]
10. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-associated neutropenia.
Dunleavy K; Tay K; Wilson WH
Semin Hematol; 2010 Apr; 47(2):180-6. PubMed ID: 20350665
[TBL] [Abstract][Full Text] [Related]
13. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
Jpn J Clin Oncol; 2011 Jun; 41(6):764-9. PubMed ID: 21459892
[TBL] [Abstract][Full Text] [Related]
14. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
[TBL] [Abstract][Full Text] [Related]
15. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
[No Abstract] [Full Text] [Related]
16. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
17. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Anglin P; Strauss BA; Brandwein JM
Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
[TBL] [Abstract][Full Text] [Related]
19. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
Kato H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
[No Abstract] [Full Text] [Related]
20. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
[No Abstract] [Full Text] [Related]
[Next] [New Search]